# Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

> **NCT03272425** · PHASE1 · COMPLETED · sponsor: **Ardea Biosciences, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** lesinurad/allopurinol 200/300 FDC tablets
- **DRUG:** lesinurad 200 mg
- **DRUG:** allopurinol 300 mg

## Key facts

- **NCT ID:** NCT03272425
- **Lead sponsor:** Ardea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-14
- **Primary completion:** 2017-10-04
- **Final completion:** 2017-10-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03272425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03272425, "Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03272425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*